Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target from $18 to $19.
Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target from $18 to $19.
More on BLCO
FDA & biotech Benzinga
Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early ReliefBausch + Lomb reports Phase 2 data for eye pain drug BL1332, showing early relief and strong safety despite missing its primary endpoint.

Benzinga
Bausch + Lomb Reports Phase 2 Results For BL1332; Primary Endpoint Missed, Exploratory Analyses Show Pain Relief And Faster Corneal HealingBoth BL1332 doses demonstrated numerically greater pain relief than vehicle across all primary, secondary and exploratory pain analyses; the primary endpoint at 24 hours was not metExploratory…
